» Articles » PMID: 32971863

Phospholipase D1 and D2 Synergistically Regulate Thrombus Formation

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Sep 25
PMID 32971863
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we reported that phospholipase D1 (PLD1) and PLD2 inhibition by selective PLD1 and PLD2 inhibitors could prevent platelet aggregation in humans, but not in mice. Moreover, only the PLD1 inhibitor, but not PLD2 inhibitor, could effectively prevent thrombus formation in mice, indicating that PLD might play different roles in platelet function in humans and mice. Although PLD1 and PLD2 were reported to be implicated in thrombotic events, the role of PLD in mice remains not completely clear. Here, we investigated the role of PLD1 and PLD2 in acute pulmonary thrombosis and transient middle cerebral artery occlusion-induced brain injury in mice. The data revealed that inhibition of PLD1, but not of PLD2, could partially prevent pulmonary thrombosis-induced death. Moreover, concurrent PLD1 and PLD2 inhibition could considerably increase survival rate. Likewise, inhibition of PLD1, but not PLD2, partially improved ischemic stroke and concurrent inhibition of PLD1, and PLD2 exhibited a relatively better protection against ischemic stroke, as evidenced by the infarct size, brain edema, modified neurological severity score, rotarod test, and the open field test. In conclusion, PLD1 might play a more important role than PLD2, and both PLD1 and PLD2 could act synergistically or have partially redundant functions in regulating thrombosis-relevant events.

Citing Articles

Inhibition of phospholipase D promotes neurological function recovery and reduces neuroinflammation after spinal cord injury in mice.

Ke H, Bai F, Li Z, Zhu Y, Zhang C, Li Y Front Cell Neurosci. 2024; 18:1352630.

PMID: 38572075 PMC: 10987874. DOI: 10.3389/fncel.2024.1352630.

References
1.
McFadyen J, Schaff M, Peter K . Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol. 2018; 15(3):181-191. DOI: 10.1038/nrcardio.2017.206. View

2.
Frohman M . The phospholipase D superfamily as therapeutic targets. Trends Pharmacol Sci. 2015; 36(3):137-44. PMC: 4355084. DOI: 10.1016/j.tips.2015.01.001. View

3.
Thielmann I, Stegner D, Kraft P, Hagedorn I, Krohne G, Kleinschnitz C . Redundant functions of phospholipases D1 and D2 in platelet α-granule release. J Thromb Haemost. 2012; 10(11):2361-72. DOI: 10.1111/j.1538-7836.2012.04924.x. View

4.
Kang D, Choi C, Cho Y, Tian H, Paolo G, Choi K . Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cells. J Exp Med. 2015; 212(8):1219-37. PMC: 4516794. DOI: 10.1084/jem.20141254. View

5.
Stegner D, Thielmann I, Kraft P, Frohman M, Stoll G, Nieswandt B . Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report. Arterioscler Thromb Vasc Biol. 2013; 33(9):2212-7. DOI: 10.1161/ATVBAHA.113.302030. View